Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary

Takeda Pharmaceutical

29/10/2026 12:12

Takeda Pharmaceutical Company Limited 4502.T reported quarterly adjusted earnings of JPY116.95​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of JPY-7.48.  The mean expectation of three analysts for the quarter was for earnings of JPY45.38 per share. Wall Street expected results to range from JPY45.30  to JPY45.45 per share.
Revenue rose 6.7% to JPY1.19 trillion from a year ago; analysts expected JPY1.16 trillion. 
Takeda Pharmaceutical Company Limited's reported EPS for the quarter was JPY116.95​.
The company reported quarterly net income of JPY192.43 billion.
Takeda Pharmaceutical Company Limited shares had risen by 9.1% this quarter and gained 30.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 9.4% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Takeda Pharmaceutical Company Limited is JPY6,800.00, about 4.8% above its last closing price of JPY6,471.00
This summary was machine generated from LSEG data October 29 at 12:12 p.m. UTC. ​All figures in yen unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
113.49 billion
205.32 billion
Beat
Jun. 30 2026 
153.72 billion
201.42 billion
Beat
Mar. 31 2026 
6.38 billion
-13.62 billion
Missed
Dec. 31 2025 
163.90 billion
168.82 billion
Beat